Look­ing past Big Phar­ma ri­vals, Blue­print buys a pre­clin­i­cal biotech for $250M+

13 hours ago
Deals

Bob Langer biotech's lead cell ther­a­py re­mains on FDA hold, but re­searchers now may know the cause

13 hours ago
Cell/Gene Tx

Thanks­giv­ing edi­tion: Top 15 End­points sto­ries of 2021; Can you name that vac­cine?; Mer­ck­'s Covid an­tivi­ral dis­ap­points; FDA nom­i­nee's in­dus­try ties; and more

2 days ago
Weekly

UP­DAT­ED: Mer­ck shares slide as re­sponse to its oral Covid an­tivi­ral plunges on lat­est up­date ahead of ad­comm

3 days ago
FDA+

What were End­points read­ers tun­ing in­to this year? Here’s a look at our 15 most pop­u­lar re­ports of the year (so far)

3 days ago
Bioregnum
Cell/Gene Tx

Omi­cron: Re­searchers scram­ble as new coro­n­avirus mu­ta­tion takes flight around the globe — Pfiz­er/BioN­Tech, Mod­er­na vow swift re­sponse

3 days ago
Coronavirus

BD an­nounces an­oth­er ex­pan­sion, this time in San Diego

5 days ago
R&D

Covid-19 roundup: Pfiz­er sues for­mer em­ploy­ee for steal­ing vac­cine se­crets; Eu­ro­pean of­fi­cials rec­om­mend vac­cine boost­ers ahead of win­ter surge

5 days ago
Coronavirus

FDA com­mish nom­i­nee's fi­nan­cial dis­clo­sures re­veal a vast web of in­dus­try ties. Will they mat­ter?

5 days ago
People
FDA+

FDA asks court for 55 years to com­plete a FOIA re­quest on the Pfiz­er/BioN­Tech vac­cine

5 days ago
FDA+

UP­DAT­ED: FDA hits the red light on an ear­ly-stage AML study af­ter a pa­tient dies

5 days ago
R&D
FDA+

Eu­rope changes its tune on Covid-19 vac­cine IP, ad­vo­cat­ing now for a 'tar­get­ed waiver'

5 days ago
Pharma
Coronavirus

The deal for BeiGene's mas­sive new US man­u­fac­tur­ing and R&D site is com­plete, and it plans to pour in 'sev­er­al hun­dred mil­lion dol­lars' soon

5 days ago
Manufacturing

Af­ter a rocky decades-long jour­ney, Take­da’s CMV drug gets FDA OK

5 days ago
FDA+

UP­DAT­ED: Mer­ck­'s pause on an HIV pro­gram snow­balls as a Gilead-part­nered tri­al is shoved in­to lim­bo

5 days ago
Deals
R&D

BeiGene gets the ball rolling on its 3rd IPO — and this one is ex­pect­ed to fetch $3B

5 days ago
Financing
China

Tak­ing a leave of ab­sence, Am­pio Phar­ma­ceu­ti­cals CEO pass­es ba­ton to a new board mem­ber; Ax­el Hoos' can­cer biotech lands a CFO

5 days ago
Peer Review

Mar­ket­ingRx roundup: Am­gen, Lil­ly, Bio­haven mi­graine brand re­call low, study says; No­var­tis looks to re­make drug launch mod­el

6 days ago
Pharma
Marketing

Q&A: Hori­zon CEO Tim Wal­bert goes from C-suite to face of the brand

6 days ago
People
Pharma

Ho­log­ic part­ners with Black women ad­vo­cates on uter­ine fi­broids cam­paign to im­prove di­ag­noses and treat­ment

6 days ago
Pharma
Marketing

J&J’s neu­ro­science re­nais­sance? Janssen R&D chief ready­ing for 'gold­en age'

6 days ago
R&D
Pharma

$107B in 2+ years? Pfiz­er’s Covid-19 vac­cine may re­de­fine ‘megablock­buster’ by 2022 — an­a­lyst

6 days ago
Pharma
Coronavirus

Did Eu­rope blun­der in its Covid vac­cine picks? Pas­cal So­ri­ot points to a po­ten­tial mis­take — and jabs back over de­lays

6 days ago
Coronavirus

House com­mit­tee wants for­mer FDA com­mis­sion­er to come clean on Covid-re­lat­ed po­lit­i­cal in­ter­fer­ence

6 days ago
FDA+
1234 Next page Last page